Ace Therapeutics has extensive experience in the field of oligonucleotide drug development. We provide a full range of services to clients worldwide for the development of oligonucleotides for the treatment of liver disease. Our services include oligonucleotide drug screening, potency testing, DMPK, and other services. Based on our professional team and well-established technology platform, we help your project progress while saving you valuable time.
Oligonucleotide drugs are the third generation of innovative drugs after small molecule drugs and antibody drugs, which mainly include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and microRNAs (miRNAs). Due to the unique mechanism of action of oligonucleotide drugs, it is very promising to fill the gap therapeutic area of traditional drugs. Based on our PhD scientists, rich technology platform, and extensive experience in oligonucleotide drug development, we provide the most scientific and professional guidance and services to our global clients in the development of oligonucleotide drugs for liver disease treatment projects.
What Can We Do?
Oligonucleotide Drug Development Services for Liver Disease
Research has shown that oligonucleotides accumulate in the liver when applied systemically to the body, which is more conducive to the development of oligonucleotide drugs for the treatment of liver disease.Ace Therapeutics provides a one-stop research service platform for the development of oligonucleotide drugs for liver disease to facilitate the smooth development of your research project.
- Oligonucleotides Synthesis Services
Ace Therapeutics has complete automated equipment for oligonucleotide synthesis. Our professional technicians will complete oligonucleotide synthesis according to specific needs to ensure the accuracy and scientific validity of the project.
The commonly used method for oligonucleotide synthesis is solid-phase synthesis, and we can provide different solid-phase carriers to meet the needs of different experimental projects.
- Oligonucleotides In Vitro Screening Services
Ace Therapeutics has built high-throughput in vitro screening platforms for different oligonucleotide drugs. Based on our libraries of different sizes, ASOs, siRNAs, and miRNAs can be screened efficiently and in high quality according to the needs of our clients' research projects for the development of potential liver disease drugs.
- For siRNA and miRNA, our in vitro screening services include well plate screening technology and microarray screening technology.
- For ASOs, we have optimized our high-throughput screening process to enable the simultaneous detection of thousands of ASOs in vitro and the final identification of candidate ASOs.
Preclinical Pharmacology Services
Ace Therapeutics provides clients with a one-stop research platform to evaluate the therapeutic effects of candidate oligonucleotides in liver disease. Our platform offers a full range of assays for oligonucleotide candidates, from biological characterization to model-based assays. Our scientists will design the most appropriate assay for your research project to facilitate the successful execution of your study.
Different in vitro and in vivo liver disease models have been established for the evaluation of candidate oligonucleotide drugs for the treatment of liver disease.
- Determining Dosing Regimen
Based on in vivo liver disease models, we provide optimized and improved services for dosing, route administration, and other aspects. We have well-established systems for evaluating liver disease and use them to determine the most appropriate dosing regimen.
We provide comprehensive bioanalytical services for oligonucleotide drugs.
Although oligonucleotides are promising therapeutics, the introduction of exogenous genes may have some toxic effects on the body, in addition to the off-target effects of oligonucleotides that may produce toxic reactions. We have designed well-established toxicological study systems, such as animal sign observation and pathological investigation to evaluate the toxicity of drug candidates.
With the inherent preference for oligonucleotides to accumulate in the liver, Ace Therapeutics believes that it is a very promising way to develop oligonucleotide drugs for liver disease treatment to reduce the risk of liver disease to human health. We have a professional team and advanced technology to ensure the smooth running of your research project. If you would like to learn more about our services, please feel free to contact us.
Reference
- Niemietz, C., et al., Therapeutic oligonucleotides targeting liver disease: Ttr amyloidosis. Molecules, 2015. 20(10): p. 17944-17975.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
